These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1296011)

  • 41. The mild hypertension dilemma: results of the British MRC trial.
    Miall WE
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):12S-21S. PubMed ID: 3098929
    [No Abstract]   [Full Text] [Related]  

  • 42. The Mayo three-community hypertension control program. V. Cost-effectiveness of intervention.
    Christianson JB; Krishan I; Nobrega FT; Davis CS; Smoldt RK; Harris AM
    Mayo Clin Proc; 1981 Jan; 56(1):11-6. PubMed ID: 6779059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Influential factors of treatment cost of antihypertensive drugs for hypertensive patient in community].
    Feng R; Wang Z; Cui Y; Wang X; Wang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 40(3):291-7. PubMed ID: 25832531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. First-line drugs for hypertension.
    Spence JD
    CMAJ; 2001 Jan; 164(2):176-8. PubMed ID: 11332306
    [No Abstract]   [Full Text] [Related]  

  • 45. [Economic evaluation of hypertension control program].
    Tanaka H; Nakayama T; Yamamoto T; Tanaka H; Yoshi-ike N; Yamaguchi M
    Nihon Rinsho; 1992 May; 50 Suppl():536-41. PubMed ID: 1512994
    [No Abstract]   [Full Text] [Related]  

  • 46. Ophthalmologists and cost uncertainty.
    Taylor HR
    Clin Exp Ophthalmol; 2014 Dec; 42(9):904-5. PubMed ID: 24646008
    [No Abstract]   [Full Text] [Related]  

  • 47. Definition of the dilemma of the scope of diagnostic investigation in the community hypertension program.
    Blaufox MD
    Bull N Y Acad Med; 1976; 52(6):671-9. PubMed ID: 823990
    [No Abstract]   [Full Text] [Related]  

  • 48. [Cost benefit analysis in the health services].
    Luković G
    Lijec Vjesn; 1975 Mar; 97(3):164-6. PubMed ID: 808675
    [No Abstract]   [Full Text] [Related]  

  • 49. Cost-benefit analysis of regional neurosurgical care.
    Michaels J
    BMJ; 1990 Nov; 301(6761):1163. PubMed ID: 2123721
    [No Abstract]   [Full Text] [Related]  

  • 50. Editorial: Coronary heart-disease in Edinburgh and Stockholm.
    Lancet; 1976 Feb; 1(7956):402-3. PubMed ID: 55656
    [No Abstract]   [Full Text] [Related]  

  • 51. Community health promotion programs.
    Luepker RV
    Soc Sci Med; 1993 Dec; 37(12):1585. PubMed ID: 8303342
    [No Abstract]   [Full Text] [Related]  

  • 52. Coronary disease in the community.
    Goble AJ
    Aust Nurses J; 1971 Jul; 1(1):26-8. PubMed ID: 5211155
    [No Abstract]   [Full Text] [Related]  

  • 53. [The pharmaco-economics of the treatment of arterial hypertension: data and controversies].
    Rorive G; Delporte JP
    Bull Mem Acad R Med Belg; 1998; 153(7-9):317-21; discussion 322-4. PubMed ID: 10100395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Moderately elevated blood pressure. A report from SBU, the Swedish Council on Technology Assessment in Health Care.
    J Intern Med Suppl; 1995; 737():1-225. PubMed ID: 9043531
    [No Abstract]   [Full Text] [Related]  

  • 55. Hypertension, a health economics perspective.
    Alcocer L; Cueto L
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):147-55. PubMed ID: 19124418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

  • 57. Community attributable risk: its economic dimensions.
    Wilhelmsen L
    J Hum Hypertens; 1992 Dec; 6(6):469-72. PubMed ID: 1296011
    [No Abstract]   [Full Text] [Related]  

  • 58. Costs and benefits of community programmes for the control of hypertension.
    Nissinen A; Tuomilehto J; Enlund H; Kottke TE
    J Hum Hypertens; 1992 Dec; 6(6):473-9. PubMed ID: 1296012
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.